tetano
Editor, Senior Moderator
J Korean Med Sci
. 2023 Jun 19;38(24):e209.
doi: 10.3346/jkms.2023.38.e209. New-Onset Fulminant Type 1 Diabetes Following SARS-CoV-2 Protein Subunit Vaccine: A Case Report and Literature Review
Lanhui Huang[SUP] 1 [/SUP], Min Liang[SUP] 2 [/SUP], Yuling He[SUP] 3 [/SUP]
Affiliations
The ravages of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) worldwide have sped up the development of relevant vaccines, which is accompanied by public concerns over possible adverse effects. We report a rare case of a 39-year-old woman who suffered from severe hyperglycemia and ketoacidosis with normal hemoglobin A1c four days after SARS-CoV-2 protein subunit vaccine, which is consistent with the diagnosis of fulminant type 1 diabetes (FT1D). She received insulin therapy and recovered after 24 days from onset of the symptoms. This is the first case of new-onset FT1D after SARS-CoV-2 protein subunit vaccination and one of only six that developed after any form of SARS-CoV-2 vaccination. We hope to raise awareness of this potential adverse consequence and recommend careful monitoring after vaccination in patients even without a medical history of diabetes.
Keywords: Adverse Effects; Fulminant Type 1 Diabetes; Protein Subunit Vaccine; SARS-CoV-2 Vaccine.
. 2023 Jun 19;38(24):e209.
doi: 10.3346/jkms.2023.38.e209. New-Onset Fulminant Type 1 Diabetes Following SARS-CoV-2 Protein Subunit Vaccine: A Case Report and Literature Review
Lanhui Huang[SUP] 1 [/SUP], Min Liang[SUP] 2 [/SUP], Yuling He[SUP] 3 [/SUP]
Affiliations
- PMID: 37337812
- DOI: 10.3346/jkms.2023.38.e209
The ravages of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) worldwide have sped up the development of relevant vaccines, which is accompanied by public concerns over possible adverse effects. We report a rare case of a 39-year-old woman who suffered from severe hyperglycemia and ketoacidosis with normal hemoglobin A1c four days after SARS-CoV-2 protein subunit vaccine, which is consistent with the diagnosis of fulminant type 1 diabetes (FT1D). She received insulin therapy and recovered after 24 days from onset of the symptoms. This is the first case of new-onset FT1D after SARS-CoV-2 protein subunit vaccination and one of only six that developed after any form of SARS-CoV-2 vaccination. We hope to raise awareness of this potential adverse consequence and recommend careful monitoring after vaccination in patients even without a medical history of diabetes.
Keywords: Adverse Effects; Fulminant Type 1 Diabetes; Protein Subunit Vaccine; SARS-CoV-2 Vaccine.